RB1 and neoplasm: The findings presented in this case study indicate that neoadjuvant chemotherapy plus immunotherapy with subsequent concurrent chemoradiotherapy may be a bladder-preserving option for MIBC patients, especially for those with a high TMB and RB1 mutation score, and that the frequency of RB1 mutation may play a promising role in monitoring tumor recurrence.